Immunohistochemical analysis of integrins αvβ3, αvβ5 and α5β1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas

Experimental and Therapeutic Medicine

Volumn 2, Issue 1, 2011, Pages 9-19

  Fabricius, Eva Maria ^a   Wildner, Gustav Paul ^b   Kruse Boitschenko, Ute ^a   Hoffmeister, Bodo ^a   Goodman, Simon L ^c   Raguse, Jan Dirk ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Section of Pathology   (Germany)

^c MERCK KGAA   (Germany)

Author keywords

Alkaline phosphatase anti alkaline phosphatase; Cancer; Frozen sections; Immunohistochemistry; Integrins; Squamous cell carcinoma of the head and neck; 5 1; v 3; v 5

Indexed keywords

ALPHAVBETA5 INTEGRIN; FIBRINOGEN; FIBRONECTIN; INTEGRIN; LIQUID NITROGEN; OSTEOPONTIN; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOUTH CARCINOMA; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; STROMA; TUMOR GROWTH;

EID: 78751616598     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.171     Document Type: Article

References (72)

1. Rapidis AD, Keramidas T, Panangiotopoulos H, Andressakis D and Angelopoulos AP: Tumours of the head and neck in the elderly: analysis of 190 patients. J Craniomaxillofac Surg 26: 153-158, 1998.
2. Forastiere A, Koch W, Trotti A and Sidransky D: Head and neck cancer. NEngl J Med 345: 1890-1900, 2001.
3. Döbrossy L: Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24: 9-17, 2005.
4. Pai SI and Westra WH: Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 4: 49-70, 2009.
5. Tejani MA, Cohen RB and Mehra R: The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics 4: 173-185, 2010.
6. Llewellyn CD, Johnson NW and Warnakulasuriya KA: Risk factors for squamous cell carcinoma of the oral cavity in young people - a comprehensive literature review. Oral Oncol 37: 401-418, 2001.
7. Llewellyn CD, Linklater K, Bell J, Johnson NW and Warnakulasuriya KA: Squamous cell carcinoma of the oral cavity in patients aged 45 years and under: a descriptive analysis of 116 cases diagnosed in the South East of England from 1990 to 1997. Oral Oncol 39: 106-114, 2003.
8. Rutt AL, Hawkshaw MJ and Sataloff RT: Laryngeal cancer in patients younger than 30 years: a review of 99 cases. Ear Nose Throat J 89: 189-192, 2010.
9. Desgrosellier JS and Cheresh DA: Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22, 2010.
10. Stupp R and Ruegg C: Integrin inhibitors reaching the clinic. J Clin Oncol 25: 1637-1638, 2007. Comment on: Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas ADand Grossman SA: Phase Iand correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657, 2007.
11. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438: 967-974, 2005.
12. Hasina R and Lingen MW: Angiogenesis in oral cancer. J Dent Educ 65: 1282-1290, 2001.
13. Rüegg C, Dormond O and Foletti A: Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? Endothelium 9: 151-160, 2002.
14. Erovic BM, Neuchrist C, Berger U, El-Rabadi K and Burian M: Quantitation of microvessel density in squamous cell carcinoma of the head and neck by computer-aided image analysis. Wien Klin Wochenschr 117: 53-57, 2005.
15. Kurtz KA, Hoffman HT, Zimmerman MB and Robinson RA: Perineural and vascular invasion in oral cavity squamous carcinoma: increased incidence on re-review of slides and by using immunohistochemical enhancement. Arch Pathol Lab Med 29: 354-359, 2005.
16. Walsh JE, Lathers DM, Chi AC, Gillespie MB, Day TA and Young MR: Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol 8: 227-238, 2007.
17. Seiwert TY and Cohen EE Targeting angiogenesis in head and neck cancer. Semin Oncol 35: 274-285, 2008.
18. Tucker RW, Sanford KK, Handleman SL and Jones GM: Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 4: 722-731, 2003.
19. Cai W and Chen X: Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 6: 407-428, 2006.
20. Hsu AR, Veeravagu A, Cai W, Hou LC, Tse V and Chen X: Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment. Recent Pat Anticancer Drug Discov 2: 143-158, 2007.
21. Paolillo M, Russo MA, Serra M, Colombo L and Schinelli S: Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem 9: 1439-1446, 2009.
22. Sheldrake HMand Patterson LH: Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets 9: 519-540, 2009.
23. Rathinam R and Alahari SK: Important role of integrins in the cancer biology. Cancer Metastasis Rev 29: 223-237, 2010.
24. Dechantsreiter MA, Planker E, Mathä B, Lohof E, Hölzemann G, Jonczyk A, Goodman SL and Kessler H: N-Methylated cyclic RGDpeptides as highly active and selective alpha (V) beta (3) integrin antagonists. J Med Chem 42: 3033-3040, 1999.
25. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M and Nabors LB: Randomized phase IIstudy of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008, with comment: Chamberlain MC: Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma? J Clin Oncol 27: 1921-1922, 2009.
26. Reardon DA, Nabors LB, Stupp R and Mikkelsen T: Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. Expert Opin Investig Drugs 17: 1225-1235, 2008.
27. Raguse JD, Gath HJ, Bier J, Riess H and Oettle H: Cilengitide (EMD121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40: 228-230, 2004.
28. Hynes RO: Integrins: bidirectional, allosteric signaling machines. Cell 110: 673-687, 2002.
29. Preissner KT: Structure and biological role of vitronectin. Annu Rev Cell Biol 7: 275-310, 1991.
30. Seiffert D and Smith JW: The cell adhesion domain in plasma vitronectin is cryptic. J Biol Chem 272: 13705-13710, 1997.
31. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KAF, Stein H and Mason DY: Immunoenzymatic labeling of monoclonal antibodies using immune complexes of complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAPComplexes). J Histochem Cytochem 32: 219-229, 1984.
32. Fabricius E-M, Langford A, Bier J, Hell B, Wildner G-P and Blümcke S: Immunohistochemical characterization of E48 and CD44-v6 expression in head and neck carcinomas. Cancer J 10: 325-330, 1997.
33. Fabricius E-M, Guschmann M, Wildner G-P, Langford A, Hell B and Bier J: Divergent immunohistochemical E48 and CD44-v6 antigen expression patterns between lymph node metastases and primary squamous cell carcinomas in the head and neck region. Cancer J 11: 153-159, 1998.
34. Fabricius E-M, Guschmann M, Langford A, Hell B and Bier J: Immunhistochemical assessment of the tumour-associated epitopes CD44v6 and E48 in tumour-free lymph nodes from patients with squamous cell carcinoma in the head-neck region. Anal Cell Pathol 20: 115-129, 2000.
35. Remmele W and Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Scores (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammagewebe. Pathologe 8: 138-140, 1987.
36. Sachs L: Angewandte Statistik - Anwendung statistischer Methoden. 11. Auflage Springer Verlag, Berlin, pp889, 2004.
37. Jones J, Watt FMand Speight PM: Changes in the expression of alpha v integrins in oral squamous cell carcinomas. J Oral Pathol Med 26: 63-68, 1997.
38. Thomas GJ, Jones J and Speight PM: Integrins and oral cancer. Oral Oncol 33: 381-388, 1997.
39. Vitolo D, Ciocci L, Ferrauti P, Cicerone E, Gallo A, De Vincentiis Mand Baroni CD: Alpha5 integrin distribution and TGFbeta1 gene expression in supraglottic carcinoma: their role in neoplastic local invasion and metastasis. Head Neck 22: 48-56, 2000.
40. Thomas GJ and Speight PM: Cell adhesion molecules and oral cancer. Crit Rev Oral Biol Med 12: 479-498, 2001.
41. Kramer RH, Shen X and Zhou H: Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev 24: 35-45, 2005.
42. Thomas GJ, Nystrom ML and Marshall JF: Alphavbeta6 integrin in wound healing and cancer of the oral cavity. J Oral Pathol Med 35: 1-10, 2006.
43. Reinartz J, Schäfer B, Batrla R, Klein CE and Kramer MD: Plasmin abrogates alpha v beta 5-mediated adhesion of a human keratinocyte cell line (HaCaT) to vitronectin. Exp Cell Res 220: 274-282, 1995.
44. Ziober BL, Silverman SS, Jr and Kramer RH: Adhesive mechanisms regulating invasion and metastasis in oral cancer. Crit Rev Oral Biol Med 12: 499-510, 2001.
45. Lyons AJ and Jones J: Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int J Oral Maxillofac Surg 36: 671-679, 2007.
46. Villaret AB, Schreiber A, Facchetti F, Fisogni S, Lonardi S, Lombardi D, Cocco D, Redaelli de Zinis LO and Nicolai P: Immunostaining patterns of CD31 and podoplanin in previously untreated advanced oral/oropharyngeal cancer: prognostic implications. Head Neck 32: 786-792, 2010.
47. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Pöpperl G, Holtmannspötter M, Kretzschmar HA, Kessler H, Tonn JC, Schwaiger M and Beer AJ: Imaging of integrin {alpha}v{beta}3 expression in patients with malignant glioma by [18F]galacto-RGDpositron emission tomography. Neuro Oncol 11: 861-870, 2009.
48. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M and Buck CA: Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50: 6757-6764, 1990.
49. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ and DeWaal RM: Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71: 320-324, 1997. Erratum in: Int J Cancer 72: 706-707, 1997.
50. Sato T, Konishi K, Kimura H, Maeda K, Yabushita K, Tsuji Mand Miwa A: Vascular integrin beta 3 and its relation to pulmonary metastasis of colorectal carcinoma. Anticancer Res 21: 643-647, 2001.
51. Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen Aand Deisseroth A: Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. Cancer Gene Ther 14: 346-353, 2007.
52. Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nährig J, Watzlowik P, Wester HJ, Harbeck Nand Schwaiger M: Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGDPET. J Nucl Med 49: 255-259, 2008.
53. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, Dirix LY, Ranieri G, Miceli Rand Cheresh DA: Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 4: 2625-2634, 1998.
54. Vonlaufen A, Wiedle G, Borisch B, Birrer S, Luder Pand Imhof BA: Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. Mod Pathol 14: 1126-1132, 2001.
55. Schnell O, Krebs B, Wagner E, Romagna A, Beer AJ, Grau SJ, Thon N, Goetz C, Kretzschmar HA, Tonn JCand Goldbrunner RH: Expression of integrin alphavbeta3 in gliomas correlates with tumor grade and is not restricted to tumor vasculature. Brain Pathol 18: 378-386, 2008.
56. Zannetti A, Del Vecchio S, Iommelli F, Del Gatto A, De Luca S, Zaccaro L, Papaccioli A, Sommella J, Panico M, Speranza A, Grieco P, Novellino E, Saviano M, Pedone Cand Salvatore M: Imaging of alphavbeta3 expression by a bifunctional chimeric RGDpeptide not cross-reacting with alphavbeta5. Clin Cancer Res 15: 5224-5233, 2009.
57. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi Mand Rüegg C: CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 68: 7323-7331, 2008.
58. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, Hanks SK and Cheresh DA: Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 69: 1383-1391, 2009.
59. Vocca I, Franco P, Alfano D, Votta G, Carriero MV, Estrada Y, Caputi M, Netti PA, Ossowski Land Stoppelli MP: Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation. Int J Cancer 124: 316-325, 2009.
60. Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas Cand Cohen-Jonathan Moyal E: Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma. Cancer Res 69: 3308-3316, 2009.
61. Färber K, Synowitz M, Zahn G, Vossmeyer D, Stragies R, van Rooijen Nand Kettenmann H: An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci 39: 579-585, 2008.
62. Morozevich GE, Kozlova NI, Cheglakov IB, Ushakova NA, Preobrazhenskaya ME and Berman AE: Implication of alpha5beta1 integrin in invasion of drug-resistant MCF-7/ADRbreast carcinoma cells: a role for MMP-2 collagenase. Biochemistry 73: 791-796, 2008.
63. Morozevich G, Kozlova N, Cheglakov I, Ushakova Nand Berman A: Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle 8: 2219-2225, 2009.
64. Lee MY, Huang JP, Chen YY, Aplin JD, Wu YH, Chen CY, Chen PCand Chen CP: Angiogenesis in differentiated placental multipotent mesenchymal stromal cells is dependent on integrin alpha5beta1. PLoSOne 4: E6913, 2009.
65. Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Löffler KU, Adamis AP and Knolle J: Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol 127: 1329-1335, 2009.
66. Morgan MR, Byron A, Humphries MJ and Bass MD: Giving off mixed signals-distinct functions of alpha5beta1 and alphavbeta3 integrins in regulating cell behaviour. IUBMBLife 61: 731-738, 2009.
67. Carter A: Integrins as target: first phase III trial launches, but questions remain. J Natl Cancer Inst 102: 675-677, 2010.
68. Wittekind Ch, Meyer HJ and Bootz F (eds): TNM Klassifikation Maligner Tumoren. UICCInternational Union Against Cancer. 6. Aufl. Korr. Nachdruck. Kopf- und Halstumoren, pp19-52, 2005.
69. Cheresh DAand Spiro RC: Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. J Biol Chem 262: 17703-17711, 1987.
70. Weinacker A, Chen A, Agrez M, Cone RI, Nishimura S, Wayner E, Pytela Rand Sheppard D: Role of the integrin alpha v beta 6 in cell attachment to fibronectin - heterologous expression of intact and secreted forms of the receptor. J Biol Chem 269: 6940-6948, 1994.
71. Wayner EA, Carter WG, Piotrowicz RSand Kunicki TJ: The function of multiple extracellular matrix receptors in mediating cell adhesion to extracellaular matrix: preparation of monoclonal antibodies to the fibronectin receptor that specifically inhibit cell adhesion to fibronectin and react with platelet glycoprotein Ic-IIa. J Cell Biol 107: 1881-1891, 1988.
72. Seiffert D, Ciambrone G, Wagner NV, Binder BRand Loskutoff DJ: The somatomedin Bdomain of vitronectin. Structural requirements for the binding and stabilization of active type 1 plasminogen activator inhibitor. J Biol Chem 269: 2659-2666, 1994.